mipomersen
Selected indexed studies
- Mipomersen. (, 2006) [PMID:29999702]
- Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. (Curr Atheroscler Rep, 2019) [PMID:31741187]
- Mipomersen and its use in familial hypercholesterolemia. (Expert Opin Pharmacother, 2019) [PMID:30526168]
_Worker-drafted node — pending editorial review._
Connections
mipomersen is a side effect of
Sources
- Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. (2019) pubmed
- Mipomersen. (2006) pubmed
- Mipomersen and its use in familial hypercholesterolemia. (2019) pubmed
- Mipomersen sodium: first global approval. (2013) pubmed
- Mipomersen(Archived). (2026) pubmed
- Mipomersen. (2010) pubmed
- Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes. (2022) pubmed
- A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. (2017) pubmed
- Familial hypercholesterolemia. (2015) pubmed
- Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. (2022) pubmed